Search CTL/CD8+ T-Cell Epitope Database

Found 73 matching records:

Displaying record number 1770

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp120(311-320)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	human(A*02)
Immunogen	HIV-1 infection
Experimental methods
Keywords	rate of progression, acute/early infection

Notes

The CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A*02, A*03, and B*07 was studied in eight HIV-1-infected subjects, two with acute infection, five with chronic, and one long-term non-progressor (LTNP)
2 to 17 epitopes were recognized in a given individual, A*02-restricted CTL response tended to be narrow and never dominated the response, and 25/27 epitopes were targeted by at least one person.

References

Day2001 C. L. Day, A. K. Shea, M. A. Altfeld, D. P. Olson, S. P. Buchbinder, F. M. Hecht, E. S. Rosenberg, B. D. Walker, and S. A. Kalams. Relative dominance of epitope-specific cytotoxic T-lymphocyte responses in human immunodeficiency virus type 1-infected persons with shared HLA alleles. J. Virol., 75(14):6279-91, Jul 2001. URL: http://jvi.asm.org/cgi/content/full/75/14/6279. PubMed ID: 11413294. Show all entries for this paper.

Displaying record number 60103

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	Env(311-320)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	RI10
Species (MHC/HLA)	human(A*02)
Immunogen	HIV-1 infection
Experimental methods	CD8 T-cell Elispot - IFNγ, Flow cytometric T-cell cytokine assay
Keywords	rate of progression, optimal epitope

Notes

Correlation between HLA class I and spontaneous control of HIV-1 was significant for 7-8 epitopes when 341 chronic, HIV-infected subjects, divided into controllers and non-controllers, were tested for EliSpot responses to 257 optimally defined epitopes. 21 epitopes were associated with viral progression. Protective epitopes tend to cluster in regions of critical stability for the protein, therefore constraining escape.
RGPGRAFVTI had a significantly positive association with HLA A*02; it was recognized by 13/117 A*02-positive subjects and 4/149 A*02-negative subjects.
RGPGRAFVTI was significantly protective, associated with viral control when restricted by HLA-A*02 in a cohort of 245 controllers and 96 progressors.

References

Pereyra2014 Florencia Pereyra, David Heckerman, Jonathan M. Carlson, Carl Kadie, Damien Z. Soghoian, Daniel Karel, Ariel Goldenthal, Oliver B. Davis, Charles E. DeZiel, Tienho Lin, Jian Peng, Alicja Piechocka, Mary Carrington, and Bruce D. Walker. HIV Control Is Mediated in Part by CD8+ T-Cell Targeting of Specific Epitopes. J. Virol., 88(22):12937-12948, Nov 2014. PubMed ID: 25165115. Show all entries for this paper.

Displaying record number 1106

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp120(311-320 IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	human(A*0201)
Immunogen
Experimental methods
Keywords	optimal epitope

Notes

C. Brander notes this is an A*0201 epitope.

References

Llano2019 Anuska Llano, Samandhy Cedeño, Sandra Silva Arrieta, and Christian Brander. The 2019 Optimal HIV CTL Epitopes Update: Growing Diversity in Epitope Length and HLA restriction. 2019. Show all entries for this paper.

Displaying record number 759

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp160(318-327 IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	human(A*0201)
Immunogen	in vitro stimulation or selection
Experimental methods
Keywords

Notes

This epitope stimulates a CTL line derived from an HIV negative donor.
This immunogenic peptide does not have the known binding motif for A2.1.
The same optimal peptide for this human HLA-A2.1 epitope was observed for a murine H-2 D^d epitope.

References

Alexander-Miller1996 M. A. Alexander-Miller, K. C. Parker, T. Tsukui, C. D. Pendleton, J. E. Coligan, and J. A. Berzofsky. Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-1 Envelope protein to human cytotoxic T lymphocytes. Int. Immunol., 8:641-649, 1996. PubMed ID: 8671651. Show all entries for this paper.

Displaying record number 52295

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp160(318-327 IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	LR25
Subtype	B
Species (MHC/HLA)	mouse(A*0201)
Immunogen	vaccine
Experimental methods
Keywords	binding affinity, vaccine-induced immune responses, immunodominance

Vaccine Details

Vaccine type	peptide
Vaccine strain	B clade LAI
Adjuvant	Incomplete Freund's Adjuvant (IFA), Montanide (ISA 720), P30, PLG

Notes

The stability of peptide binding to HLA-A2.1 was determined for six HLA-A2.1 peptides included in this vaccine study -- ILKEPVHGV (RT), SLYNTVATL (p17), SLLNATDIAV (gp41) and LLWKGEGAV (RT) all bound with high affinity comparable to an influenza epitope reference (GILGFVFTL), while RGPGRAFVTI and VIYQYMDDL bound with a lower affinity (relative binding activity = 0.01).
The four high-affinity peptides formed stable complexes with half-lives ranging between 8 and 32 hours, while the low affinity peptides had half lives of less than an hour.
HLA-A2.1 transgenic mice were immunized with the six HIV-1 peptides and P30, as a universal T-helper epitope, with IFA or Montanide or microspheres as adjuvants.
All peptides except VIYQYMDDL induced a strong CTL response in Cr-release assays - stronger responses were observed when peptides were delivered alone, indicating immunodominance when the combination was used.

References

Peter2001 Katrin Peter, Ying Men, Giuseppe Pantaleo, Bruno Gander, and Giampietro Corradin. Induction of a Cytotoxic T-Cell Response to HIV-1 Proteins with Short Synthetic Peptides and Human Compatible Adjuvants. Vaccine, 19(30):4121-4129, 20 Jul 2001. PubMed ID: 11457536. Show all entries for this paper.

Displaying record number 60101

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	Env(311-320)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	RI10
Species (MHC/HLA)	human(A*03)
Immunogen	HIV-1 infection
Experimental methods	CD8 T-cell Elispot - IFNγ, Flow cytometric T-cell cytokine assay
Keywords	rate of progression, optimal epitope

Notes

Correlation between HLA class I and spontaneous control of HIV-1 was significant for 7-8 epitopes when 341 chronic, HIV-infected subjects, divided into controllers and non-controllers, were tested for EliSpot responses to 257 optimally defined epitopes. 21 epitopes were associated with viral progression. Protective epitopes tend to cluster in regions of critical stability for the protein, therefore constraining escape.
RGPGRAFVTI had a significantly positive association with HLA A*03; it was recognized by 19/63 A*03-positive subjects and 23/278 A*03-negative subjects.
RGPGRAFVTI was significantly protective, associated with viral control when restricted by HLA-A*03 in a cohort of 245 controllers and 96 progressors.

References

Displaying record number 57631

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	RGP
Species (MHC/HLA)	transgenic mouse(A2)
Immunogen	vaccine
Experimental methods	Flow cytometric T-cell cytokine assay
Keywords	epitope processing, vaccine antigen design

Vaccine Details

Vaccine type	DNA prime with vaccinia boost, polyepitope
Vaccine strain	A clade, B clade, C clade
Vaccine component	Env, Gag, Nef, Pol, Vpr

Notes

A2 mice were vaccinated with polyepitope vaccines containing 10 A2-restricted epitopes, or subsets of these epitopes, and additional alanine-augmented peptide AQMHEDIISL. Epitopes were chosen from the HIV Database Optimal Epitopes list, and were conserved among clades A, B and C.
3 basic constructs C1, C2, C3 were designed: C1 - epitopes linked together without flanking spacer residues; C2 - epitopes linked via spacer sequences to optimize the liberation of determinants by proteasomes; C3 - inserted flanking sequences to optimize TAP transport and, where necesary, additional residues to enhance proteasome epitope liberation. The 3 basic constructs were expressed in 3 vector plasmids: as individual sequences; as fusions with N-terminal ubiquitin (Ub); as fusions with C-terminal Ub.
The most immunogenic construct contained N-terminal ubiquitin for targeting the polyepitope to the proteasome and included both proteasome liberation and TAP transport optimized spacer sequence that flanked the epitopes.
This peptide was included in the constructs but did not induce response in any group of immunized animals.

References

Bazhan2010 S. I. Bazhan, L. I. Karpenko, T. N. Ilyicheva, P. A. Belavin, S. V. Seregin, N. K. Danilyuk, D. V. Antonets, and A. A. Ilyichev. Rational Design Based Synthetic Polyepitope DNA Vaccine for Eliciting HIV-Specific CD8+ T Cell Responses. Mol Immunol, 47(7-8):1507-1515, Apr 2010. PubMed ID: 20189249. Show all entries for this paper.

Displaying record number 53585

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp160(311-320)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(A2)
Immunogen	HIV-1 infection
Country	United States
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, HLA binding
Keywords	acute/early infection, optimal epitope

Notes

The most frequently targeted HLA-A*02-restricted CD8+ T-cell epitopes in chronic infection were significantly less frequently recognized during primary infection. This epitope was recognized both in acute and chronic infection, but slightly more frequently in chronic infection.

References

Altfeld2005a Marcus Altfeld, Todd M. Allen, Elizabeth T. Kalife, Nicole Frahm, Marylyn M. Addo, Bianca R. Mothe, Almas Rathod, Laura L. Reyor, Jason Harlow, Xu G. Yu, Beth Perkins, Loren K. Robinson, John Sidney, Galit Alter, Mathias Lichterfeld, Alessandro Sette, Eric S. Rosenberg, Philip J. R. Goulder, Christian Brander, and Bruce D. Walker. The Majority of Currently Circulating Human Immunodeficiency Virus Type 1 Clade B Viruses Fail To Prime Cytotoxic T-Lymphocyte Responses against an Otherwise Immunodominant HLA-A2-Restricted Epitope: Implications for Vaccine Design. J. Virol., 79(8):5000-5005, Apr 2005. PubMed ID: 15795285. Show all entries for this paper.

Displaying record number 762

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp160(318-327 IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	human(A2)
Immunogen	vaccine
Experimental methods
Keywords

Vaccine Details

Vaccine type	vaccinia
Vaccine strain	B clade IIIB
Vaccine component	gp160

Notes

Individual was immunized with rec vaccinia gp160 IIIB and boosted with purified gp160.
Lysis only occurs with IIIB P18 peptide pulsed onto autologous targets; MN, RF, SIMI P18 peptides fail to stimulate CTL.
Restimulating immune cells from gp160 IIIB vaccinees with MN, RF, or SIMI P18 did not enhance the MN, RF, or SIMI specific CTL response.

References

Achour1996 A. Achour, F. Bex, P. Hermans, A. Burny, and D. Zagury. Induction of anti-gp160 cytotoxic T cells cross-reacting with various V3 loop P18 peptides in human immunodeficiency virus type 1 envelope-immunized individuals. J. Virol., 70:6741-6750, 1996. PubMed ID: 8794311. Show all entries for this paper.

Displaying record number 54232

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp120
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	A2-RI10(gp120)
Species (MHC/HLA)	human(A2)
Immunogen	HIV-1 infection
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	rate of progression, immunodominance, early-expressed proteins

Notes

Immunodominant HIV epitopes in early, primary infection of CTLs were identified and the relative contribution of immune responses restricted to individual HLA class I molecules were studied.
The most frequently recognised epitopes also elicited the greatest CTL response.
HIV-1 Epitope sequence variability was not correlated with immunodominant versus immune sub-dominant responses.
HLA-B*57 and HLA-B*27 restricted responses were the strongest in these early and acute infections - due to dominant responses to a single epitope in each case (TW10 for B*57 and KK10 for B*27).
In the presence of HLA-B*57 and HLA-B*27 restricted responses, the relative contribution of other restricting HLA dropped greatly.

References

Altfeld2006 Marcus Altfeld, Elizabeth T. Kalife, Ying Qi, Hendrik Streeck, Mathias Lichterfeld, Mary N. Johnston, Nicole Burgett, Martha E. Swartz, Amy Yang, Galit Alter, Xu G. Yu, Angela Meier, Juergen K. Rockstroh, Todd M. Allen, Heiko Jessen, Eric S. Rosenberg, Mary Carrington, and Bruce D. Walker. HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8+ T Cell Response against HIV-1. PLoS Med., 3(10):e403, Oct 2006. PubMed ID: 17076553. Show all entries for this paper.

Displaying record number 60105

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	Env(311-320)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	RI10
Species (MHC/HLA)	human(A*31)
Immunogen	HIV-1 infection
Experimental methods	CD8 T-cell Elispot - IFNγ, Flow cytometric T-cell cytokine assay
Keywords	rate of progression, optimal epitope

Notes

Correlation between HLA class I and spontaneous control of HIV-1 was significant for 7-8 epitopes when 341 chronic, HIV-infected subjects, divided into controllers and non-controllers, were tested for EliSpot responses to 257 optimally defined epitopes. 21 epitopes were associated with viral progression. Protective epitopes tend to cluster in regions of critical stability for the protein, therefore constraining escape.
RGPGRAFVTI had a significantly positive association with HLA A*31; it was recognized by 2/15 A*31-positive subjects and 1/133 A*31-negative subjects.
RGPGRAFVTI was significantly protective, associated with viral control when restricted by HLA-A*31 in a cohort of 245 controllers and 96 progressors.

References

Displaying record number 60106

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	Env(311-320)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	RI10
Species (MHC/HLA)	human(B*40)
Immunogen	HIV-1 infection
Experimental methods	CD8 T-cell Elispot - IFNγ, Flow cytometric T-cell cytokine assay
Keywords	rate of progression, optimal epitope

Notes

Correlation between HLA class I and spontaneous control of HIV-1 was significant for 7-8 epitopes when 341 chronic, HIV-infected subjects, divided into controllers and non-controllers, were tested for EliSpot responses to 257 optimally defined epitopes. 21 epitopes were associated with viral progression. Protective epitopes tend to cluster in regions of critical stability for the protein, therefore constraining escape.
RGPGRAFVTI had a significantly positive association with HLA B*40; it was recognized by 1/6 B*40-positive subjects and 0/127 B*40-negative subjects.
RGPGRAFVTI was significantly protective, associated with viral control when restricted by HLA-B*40 in a cohort of 245 controllers and 96 progressors.

References

Displaying record number 60104

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	Env(311-320)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	RI10
Species (MHC/HLA)	human(B*4202)
Immunogen	HIV-1 infection
Experimental methods	CD8 T-cell Elispot - IFNγ, Flow cytometric T-cell cytokine assay
Keywords	rate of progression, optimal epitope

Notes

Correlation between HLA class I and spontaneous control of HIV-1 was significant for 7-8 epitopes when 341 chronic, HIV-infected subjects, divided into controllers and non-controllers, were tested for EliSpot responses to 257 optimally defined epitopes. 21 epitopes were associated with viral progression. Protective epitopes tend to cluster in regions of critical stability for the protein, therefore constraining escape.
RGPGRAFVTI had a significantly positive association with HLA B*4202; it was recognized by 1/1 B*4202-positive subjects and 3/148 B*4202-negative subjects.
RGPGRAFVTI was significantly protective, associated with viral control when restricted by HLA-B*4202 in a cohort of 245 controllers and 96 progressors.

References

Displaying record number 60102

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	Env(311-320)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	RI10
Species (MHC/HLA)	human(C*14)
Immunogen	HIV-1 infection
Experimental methods	CD8 T-cell Elispot - IFNγ, Flow cytometric T-cell cytokine assay
Keywords	rate of progression, optimal epitope

Notes

Correlation between HLA class I and spontaneous control of HIV-1 was significant for 7-8 epitopes when 341 chronic, HIV-infected subjects, divided into controllers and non-controllers, were tested for EliSpot responses to 257 optimally defined epitopes. 21 epitopes were associated with viral progression. Protective epitopes tend to cluster in regions of critical stability for the protein, therefore constraining escape.
RGPGRAFVTI had a significantly positive association with HLA C*14; it was recognized by 6/12 C*14-positive subjects and 17/266 C*14-negative subjects.
RGPGRAFVTI was significantly protective, associated with viral control when restricted by HLA-C*14 in a cohort of 245 controllers and 96 progressors.

References

Displaying record number 55110

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	Env
Epitope	`RGPGRAFVTI`	Epitope Alignment
Subtype	A, B
Species (MHC/HLA)	mouse(H-2d)
Immunogen	vaccine
Country	Finland
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay
Keywords	vaccine antigen design

Vaccine Details

Vaccine type	DNA
Vaccine strain	A clade, B clade
Vaccine component	Env, Gag

Notes

A novel mouse model was used to test the efficacy of 2 HIV DNA vaccines in protection against tumor challenge. Comparable immunogenicity between the single and multi-clade vaccines tested was seen in different mouse strains. CTL response to HIV-1-APCs was both in vivo and in vitro and this animal model was safe and not only evaluated vaccine immunogenicity but also confirmed the potency of GTU-multi-HIV vaccines.

References

Malm2007 Maria Malm, Rein Sikut, Kai Krohn, and Vesna Blazevic. GTU-MultiHIV DNA Vaccine Results in Protection in a Novel P815 Tumor Challenge Model. Vaccine, 25(17):3293-301, 30 Apr 2007. PubMed ID: 17289222. Show all entries for this paper.

Displaying record number 58376

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	H, P18-I10
Subtype	A
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Cytotoxicity assay, Intracellular cytokine staining
Keywords	mother-to-infant transmission, vaccine antigen design

Vaccine Details

Vaccine type	Bacillus BCG prime with vaccinia Ankara (MVA) boost
Vaccine strain	A clade, multiple epitope immunogen
Vaccine component	p17 Gag, p24 Gag, Other

Notes

The HIVA polyprotein contains p24, p17, and a polyepitope string of conserved epitopes. A candidate vaccine was constructed with Mycobacterium bovis bacillus Calmette-Guerin (BCG) as the vector. When mice were primed with BCG-HIVA and boosted with MVA-HIVA, the frequencies of HIV-specific CD8+ T cells producing IFN-γ were higher in adult mice vaccinated intradermally compared to newborn mice or adults vaccinated subcutaneously. HIV-specific CTL activity was higher in newborn mice than in adults. This method may provide a model for bivalent vaccination against infant HIV-1 and tuberculosis.
Epitope H (P18-I10) was used to assess the immunogenicity of the HIVA immunizations.

References

Saubi2011 Narcis Saubi, Eung-Jun Im, Raquel Fernández-Lloris, Olga Gil, Pere-Joan Cardona, Josep Maria Gatell, Tomáš Hanke, and Joan Joseph. Newborn Mice Vaccination with BCG.HIVA222 + MVA.HIVA Enhances HIV-1-Specific Immune Responses: Influence of Age and Immunization Routes. Clin. Dev. Immunol., 2011:516219, 2011. PubMed ID: 21603216. Show all entries for this paper.

Displaying record number 751

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp160(318-327 IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	vaccine
Experimental methods
Keywords	dendritic cells

Vaccine Details

Vaccine type	peptide
Vaccine strain	B clade IIIB
Vaccine component	Env V3

Notes

Successful priming with vaccination of peptide pulsed splenic dendritic cells.

References

Takahashi1993 H. Takahashi, Y. Nakagawa, K. Yokomuro, and J. A. Berzofsky. Induction of CD8+ Cytotoxic T Lymphocytes by Immunization with Syngeneic Irradiated HIV-1 Envelope Derived Peptide-Pulsed Dendritic Cells. Internatl. Immunol., 5:849-857, 1993. PubMed ID: 8398980. Show all entries for this paper.

Displaying record number 752

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp160( IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	vaccine
Experimental methods
Keywords

Vaccine Details

Vaccine type	non-replicating adenovirus
Vaccine strain	B clade IIIB
Vaccine component	Env, Rev

Notes

A good HIV-1 Env immune response using non-replicating adenovirus vectors in BALB/c mice is dependent upon the presence of the stimulatory tat/rev 5'splice-donor site sequence and the presence of Rev.
Administration of monocistronic RAd501 expressing env and RAd46 expressing rev resulted in a positive CTL response, but required two immunizations for a CTL response comparable to that induced by the bicistronic virus RAd142.
Administration of RAd501 alone gave a low CTL response, but no humoral response, suggesting a lower level of antigen may be required to stimulate CTL.

References

Bruce1999 C. B. Bruce, A. Akrigg, S. A. Sharpe, T. Hanke, G. W. Wilkinson, and M. P. Cranage. Replication-Deficient Recombinant Adenoviruses Expressing the Human Immunodeficiency Virus Env Antigen Can Induce Both Humoral and CTL Immune Responses in Mice. J. Gen. Virol., 80(Pt 10):2621-2628, 1999. PubMed ID: 10573155. Show all entries for this paper.

Displaying record number 754

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp160(318-327 IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	vaccine
Experimental methods
Keywords

Vaccine Details

Vaccine type	peptide
Vaccine strain	B clade IIIB
Vaccine component	Env V3

Notes

Exposure of CD8+ CTL to free peptide corresponding to the epitope results in strong inhibition of the CTL response to targets presensitized with the same peptide.
The authors propose this is due to a ``self-veto'', where the CTL is inactivated by a CD8+ cell carrying the appropriate peptide-MHC complex.

References

Takahashi1996 H. Takahashi, Y. Nakagawa, G. R. Leggatt, Y. Ishida, T. Saito, K. Yokomuro, and J. A. Berzofsky. Inactivation of Human Immunodeficiency Virus (HIV-1) Envelope-Specific CD8+ Cytotoxic T Lymphocytes by Free Antigenic Peptide: A Self-Veto Mechanism? J. Exp. Med., 183:879-889, 1996. PubMed ID: 8642292. Show all entries for this paper.

Displaying record number 761

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp160(318-327 IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	peptide-HLA interaction
Experimental methods
Keywords

Notes

XGPXRXXXXI are critical for binding, consistent with H-2D^d motif XGPX(RKH)XXX(X)(LIF)

References

Takeshita1995 T. Takeshita, H. Takahashi, S. Kozlowski, J. D. Ahlers, C. D. Pendleton, R. L. Moore, Y. Nakagawa, K. Yokomuro, B. S. Fox, D. H. Margulies, and J. A. Berzofsky. Molecular Analysis of the Same HIV Peptide Functionally Binding to Both a Class I and a Class II MHC Molecule. J. Immunol., 154:1973-1986, 1995. Of RGPGRAFVTI, the upper case amino acids iGPgRaFvtI are critical for binding, consistent with H-2D$d$ motif XGPX(RKH)XXX(X)(LIF). Stimulation of the HLA class II I-A$^d$ required a longer peptide, IQRGPGRAFVTI or RIQRGPGRAFVTI, and riqrgPgRaFvti were essential for binding to the Class II molecule. PubMed ID: 7530749. Show all entries for this paper.

Displaying record number 1351

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	Env( IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	I-10
Subtype	B
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	in vitro stimulation or selection
Experimental methods
Keywords	epitope processing, immunodominance, optimal epitope

Notes

The CTL line LINE-IIIB was generated by repetitive restimulation of BALB/c spleen cells with vSC-25, IIIB gp160-expressing vaccinia.
RGPGRAFVTI represents the active minimal epitope within the previously described immunodominant epitope P18IIIB (RIQRGPGRAFVTIGK, gp160(308-322)).
External processing of P18IIIB results in the removal of the 2 C-terminal residues (GK) of I-10 by ACE (angiotensin-1-converting-enzyme) in sera to produce I-10, and this processing is essential for target cell presentation of RIQRGPGRAFVTIGK.

References

Nakagawa2000 Y. Nakagawa, T. Takeshita, J. A. Berzofsky, and H. Takahashi. Analysis of the mechanism for extracellular processing in the presentation of human immunodeficiency virus-1 envelope protein-derived peptide to epitope-specific cytotoxic T lymphocytes. Immunology, 101(1):76-82, Sep 2000. PubMed ID: 11012756. Show all entries for this paper.

Displaying record number 52189

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	Env( IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	p18-I10
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	vaccine
Experimental methods
Keywords	immunodominance

Vaccine Details

Vaccine type	vaccinia, vesicular stomatitis virus (VSV)
Vaccine strain	B clade HXB2, B clade IIIB
Vaccine component	Env, Gag

Notes

Different HIV strains were used for different regions: Env IIIB, Gag HXB2
BALB/c mice were vaccinated with rec vesicular stomatitis virus (rVSV) expressing either HIV-1 Gag, Env, or both, and compared to using rec Env and Gag in vaccinia virus (rVVs). The primary response was determined by cell lysis, cytokine production and tetramer staining.
Primary CTL responses to the immunodominant Env (RGPGRAFVTI) epitope peaked 5-7 days after intraperitoneal vaccination with Env-rVSV, 40% of the CD8+ cells were tetramer positive, and this response was 6-fold higher than the response to Env-rVV.
Vaccinating with GagEnv-rVSV carrying both Gag and Env allowed recognition of both HIV-1 proteins, but at reduced levels compared to either Gag-rVSV or Env-rVSV alone.
Intranasal immunization with Env-rVSV yielded CTL responses that were strong but reduced compared to an intraperitoneal route.

References

Haglund2002a Karl Haglund, Ingrid Leiner, Kristen Kerksiek, Linda Buonocore, Eric Pamer, and John K. Rose. High-Level Primary CD8(+) T-Cell Response to Human Immunodeficiency Virus Type 1 Gag and Env Generated by Vaccination with Recombinant Vesicular Stomatitis Viruses. J. Virol., 76(6):2730-2738, Mar 2002. PubMed ID: 11861840. Show all entries for this paper.

Displaying record number 52211

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	Env( IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	p18-I10
Subtype	B
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	vaccine
Experimental methods
Keywords	immunodominance

Vaccine Details

Vaccine type	vaccinia, vesicular stomatitis virus (VSV)
Vaccine strain	B clade HXB2
Vaccine component	Env, Gag

Notes

Different HIV strains were used for different regions: Env IIIB, Gag HXB2
BALB/c mice were vaccinated with rec vesicular stomatitis virus (rVSV) expressing either HIV-1 Gag or Env, or both, and retention of memory responses and recall responses were studied by tetramer staining and IFN-gamma production.
Seven months after vaccination with Env-rVSV, 6% of the CD8+ cells were tetramer positive for the immunodominant Env epitope; these cells had a memory phenotype, CD44-Hi positive.
Env in rec vaccinia virus (Env-rVV) elicited a strong recall response, with up to 45% to the CD8+ T-cell population tetramer positive and activated (expressing CD62L-Lo), and capable of IFN-gamma production.
A prime with Env-rVSV and heterologous boost of Env-rVV gave remarkably high levels of memory cells, with approximately 1/3 of the CD8+ splenocytes being Env specific memory cells 150 days after the boost.
A Gag-rVSV or EnvGag-rVSV prime and with a heterologous Gag-rVV or EnvGag-rVV boost combination gave 40% tetramer positive CD8+ cells, but the fraction of IFN-gamma producing cells was only about 25%. Still the heterologous vector prime-boost combination showed a profound benefit.
A HIV-1 protein rVSV prime, rVV boost was a more potent combination than a vector reversal of a rVV prime and rVSV boost.

References

Haglund2002b Karl Haglund, Ingrid Leiner, Kristen Kerksiek, Linda Buonocore, Eric Pamer, and John K. Rose. Robust Recall and Long-Term Memory T-Cell Responses Induced by Prime-Boost Regimens with Heterologous Live Viral Vectors Expressing Human Immunodeficiency Virus Type 1 Gag and Env Proteins. J. Virol., 76(15):7506-7517, Aug 2002. PubMed ID: 12097563. Show all entries for this paper.

Displaying record number 52240

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp120 (V3)( IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	vaccine
Experimental methods
Keywords

Vaccine Details

Vaccine type	peptide
Vaccine strain	B clade IIIB
Vaccine component	Env V3
Adjuvant	Cholera toxin (CT), GM-CSF, IL-12, IL-18, IL-1α

Notes

Cholera toxin (CT) is a potent adjuvant used in animal studies that is not safe in humans, so combinations of cytokins were used in nasal immunization of BALB/c mice V3 peptides to attempt to replace CT as a potent adjuvant.
Peptide vaccine induced CTL activity was significantly increased by IL-1alpha , IL-18, and GMCSF given alone as adjuvant, but CT gave more potent CTL activity than any single cytokine.
Combinations of cytokins could be more potent that CT as an adjuvant. The highest tetramer binding of H-2Dd peptide-specific PBMC after nasal immunization was observed with IL-1alpha plus IL-18 as adjuvant.
Nasal immunization with HIV peptide in the presence of IL-1alpha, IL-12 and GM- CSF induced IFN-gamma-secreting cells in the cervical lymph node, the lung and the spleen, and was associated with upregulation of MHC class II and B7.1 on nonlymphocytes in NALT/nasal mucosal cells.
Consistent results were obtained for the IIIB and the MN peptides.

References

Staats2001 Herman F. Staats, Curtis P. Bradney, William M. Gwinn, Shawn S. Jackson, Gregory D. Sempowski, Hua-Xin Liao, Norman L. Letvin, and Barton F. Haynes. Cytokine Requirements for Induction of Systemic and Mucosal CTL After Nasal Immunization. J. Immunol., 167(9):5386-5394, 1 Nov 2001. PubMed ID: 11673557. Show all entries for this paper.

Displaying record number 52242

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp160(318-327 IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	vaccine
Experimental methods
Keywords	immunodominance

Vaccine Details

Vaccine type	DNA prime with vaccinia boost
Vaccine strain	B clade IIIB
Vaccine component	gp160
Adjuvant	beta-glucan lentinan, IL-2/Ig, liposome, PLG

Notes

BALB/c mice were give an oral immunization with (PLG)-encapsulated plasmid DNA expressing gp160 and a boost of rec gp160 vaccinia vectors (rVV) with addition of murine IL-2/Ig plasmid or lentinan-associated liposomes. Lentinan increased CTL activity as measured by Cr-release assays against the immunodominant epitope RGPGRAFVTI, but didn't alter Ab responses. IL-2/Ig increased both type I and II activities, and increased Env specific CTL and Abs. Administration of liposomes and PLG microparticles with adjuvants facilitated gastrointestinal uptake.

References

Wierzbicki2002 Andrzej Wierzbicki, Irena Kiszka, Hiroshi Kaneko, Dariusz Kmieciak, Thomas J Wasik, Jaroslaw Gzyl, Yutaro Kaneko, and Danuta Kozbor. Immunization Strategies to Augment Oral Vaccination with DNA and Viral Vectors Expressing HIV Envelope Glycoprotein. Vaccine, 20(9-10):1295-1307, 31 Jan 2002. PubMed ID: 11818148. Show all entries for this paper.

Displaying record number 52287

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp120( LAI)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	P18
Subtype	B
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	vaccine
Experimental methods
Keywords

Vaccine Details

Vaccine type	protein
Vaccine strain	B clade LAI
Vaccine component	Gag, gp120
Adjuvant	CpG immunostimulatory sequence (ISS)

Notes

Immunostimulatory sequences (ISS), also known as CpG motifs, stimulate innate immunity and enhance vaccine-specific immune responses.
Intranasal immunization (i.n.) of BALB/c mice was more effective than intradermal (i.d.), and immunization with a gp120-ISS conjugate was more potent than immunizing with gp120 and separate ISS molecule -- increased IgG1, IgG2a, IFN-gamma, MIP1-alpha and MIP1-beta production was observed, and only i.n. immunization gave IgA responses.
The highest mucosal CTL activity in both the Lamina Propria and the Peyer's Patch was observed following intranasal delivery with the gp120/ISS conjugate.
Cytokine, chemokine and CTL responses following gp120/ISS conjugate vaccination were CD4+ T-cell independent; gp120 specific antibodies were dependent on helper T cells.

References

Horner2001 A. A. Horner, G. F. Widhopf, J. A. Burger, K. Takabayashi, N. Cinman, A. Ronaghy, H. L. Spiegelberg, and E. Raz. Immunostimulatory DNA Inhibits IL-4-Dependent IgE Synthesis by Human B Cells. J Allergy Clin Immunol, 108(3):417-423, Sep 2001. PubMed ID: 11544462. Show all entries for this paper.

Displaying record number 52327

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp160 (V3)( IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	I10
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	vaccine
Experimental methods
Keywords	acute/early infection

Vaccine Details

Vaccine type	vaccinia
Vaccine strain	B clade IIIB
Vaccine component	gp160

Notes

During acute infection, high doses of virus result in "clonal exhaustion", a depletion of antigen specific T-cells.
Recently stimulated CTL from BALB/c mice vaccinated with gp160-vaccinia showed a dose- and time-dependent induction of apoptosis when stimulated with antigenic peptide or H-2Dd/peptide tetramers.
Restimulated CTL showed an upregulation of CD3-chain phosphorylation in comparison to cells stimulated with target cells, indicative of TCR-mediated apoptosis. Furthermore, apoptosis was inhibited by cyclosporin A and U0126, a mitogen activated kinase inhibitor specific for the ERK1/ERK2 MAPK kinase pathway, and a caspase 3 inhibitor.

References

Takahashi2002 Megumi Takahashi, Eiichi Osono, Yohko Nakagawa, Jian Wang, Jay A. Berzofsky, David H. Margulies, and Hidemi Takahashi. Rapid Induction of Apoptosis in CD8+ HIV-1 Envelope-Specific Murine CTLs by Short Exposure to Antigenic Peptide. J. Immunol., 169(11):6588-6593, 1 Dec 2002. PubMed ID: 12444171. Show all entries for this paper.

Displaying record number 52764

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp160 (V3)( HIV-IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	P18-I10
Subtype	B
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	vaccine
Patient MHC/HLA	H-2d
Experimental methods	Chromium-release assay, Cytokine production, Tetramer binding
Keywords

Vaccine Details

Vaccine type	vaccinia
Vaccine strain	B clade IIIB
Vaccine component	gp160
Adjuvant	IL-15, IL-2

Notes

IL-2 and IL-15 in vaccinia constructs were given with an HIV gp160 vaccinia vaccine to BALB/c mice. Both IL-2 and IL-15 induced strong and long-lasting antibody responses. Short-term CTL responses against HIV gp120 were enhanced by IL-2, but IL-15 enhanced both immediate CD8+ T cell responses and CD8+ T memory cells.

References

Oh2003a SangKon Oh, Jay A. Berzofsky, Donald S. Burke, Thomas A. Waldmann, and Liyanage P. Perera. Coadministration of HIV Vaccine Vectors with Vaccinia Viruses Expressing IL-15 But Not IL-2 Induces Long-Lasting Cellular Immunity. Proc. Natl. Acad. Sci. U.S.A., 100(6):3392-3397, 18 Mar 2003. PubMed ID: 12626740. Show all entries for this paper.

Displaying record number 52765

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp160( IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	P18-I10
Subtype	B
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	vaccine
Patient MHC/HLA	H-2d
Experimental methods	CD8 T-cell Elispot - IFNγ, Proliferation, Tetramer binding
Keywords

Vaccine Details

Vaccine type	vaccinia
Vaccine strain	B clade IIIB
Vaccine component	Env V3
Adjuvant	B7, ICAM, LFA-3

Notes

BALB/c mice were vaccinated with T-cell depleted splenocytes pulsed with peptides given in combination with immunostimulatory molecules B7, ICAM or LFA expressed in a recombinant pox virus. Increasing antigen gave an increased frequency of CD8+ T-cells, but the co-stimulatory molecules increased the avidity of the response.

References

Oh2003b SangKon Oh, James W Hodge, Jeffrey D Ahlers, Donald S Burke, Jeffrey Schlom, and Jay A Berzofsky. Selective Induction of High Avidity CTL by Altering the Balance of Signals from APC. J. Immunol., 170(5):2523-2530, Mar 2003. PubMed ID: 12594278. Show all entries for this paper.

Displaying record number 52786

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp120 (V3)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	vaccine
Patient MHC/HLA	H-2d
Experimental methods	Cytotoxicity assay, Tetramer binding
Keywords	kinetics, memory cells

Vaccine Details

Vaccine type	herpes simplex virus type-1 (HSV-1) amplicon
Vaccine component	gp120

Notes

Prime-boost combinations of gp120 combined with herpes simplex virus type-1 (HSV-1) amplicon particles, or gp120 in naked amplicon plasmid DNA, were compared in BLAB/c mice. Plasmid prime with particle boosts gave the strong primary (2 weeks) and memory responses (4 months).
CD8+ T-cells reached their peak 8-28 days after the initial amplicon delivery.

References

Wang2003 Lai-Xi Wang. Bioorganic Approaches towards HIV Vaccine Design. Curr. Pharm. Des., 9(22):1771-87, 2003. PubMed ID: 12871196. Show all entries for this paper.

Displaying record number 52843

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp120 (V3)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	P18-I10
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	vaccine
Experimental methods	Chromium-release assay, Flow cytometric T-cell cytokine assay
Keywords	dendritic cells, Th1, Th2, genital and mucosal immunity

Vaccine Details

Vaccine type	peptide, vaccinia
Vaccine strain	B clade 89.6, B clade IIIB
Vaccine component	gp160ΔV3
Adjuvant	Cholera toxin (CT), E. coli mutant heat labile enterotoxin (LT-R72), Incomplete Freund's Adjuvant (IFA), CpG immunostimulatory sequence (ISS)

Notes

Transcutaneous immunization (TCI) of BALB/c mice induced adjuvant-dependent HIV-1 specific CTL responses in the spleen and the gut mucosa that resulted in protection against mucosal challenge against a recombinant vaccina virus carrying HIV-1 env. Activated DCs from skin were shown to migrate to immune-inductive sites in gut mucosa and to present antigen directly to resident lymphocytes.

References

Belyakov2004 Igor M. Belyakov, Scott A. Hammond, Jeffrey D. Ahlers, Gregory M. Glenn, and Jay A. Berzofsky. Transcutaneous Immunization Induces Mucosal CTLs and Protective Immunity by Migration of Primed Skin Dendritic Cells. J. Clin. Invest., 113(7):998-1007, Apr 2004. PubMed ID: 15057306. Show all entries for this paper.

Displaying record number 53001

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp120 (V3)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Cytotoxicity assay, Tetramer binding
Keywords	vaccine antigen design

Vaccine Details

Vaccine type	herpes simplex virus type-1 (HSV-1) amplicon
Vaccine strain	B clade LAI, B clade MN
Vaccine component	gp120

Notes

BALB/c mice were immunized with HSV amplicons containing HIV-1 gp120. Helper virus free HSV-1 amplicon particles are capable of inducing potent cytoxic CD8+ T-cell and humoral immune responses to the HIV-1 antigen in mice. Previous infection with wild-type HSV-1 reduces amplicon-induced cellular immune responses to HIV gp120 modestly (40-60%), but severally reduced B-cell responses. The route of vaccination impacted the nature and level of the responses (i.m., i.d., and i. p.).

References

Hocknell2002 Peter K. Hocknell, Rebecca D. Wiley, Xiuqing Wang, Thomas G. Evans, William J. Bowers, Tomas Hanke, Howard J. Federoff, and Stephen Dewhurst. Expression of Human Immunodeficiency Virus Type 1 gp120 from Herpes Simplex Virus Type 1-Derived Amplicons Results in Potent, Specific, and Durable Cellular and Humoral Immune Responses. J. Virol., 76(11):5565-5580, Jun 2002. PubMed ID: 11991985. Show all entries for this paper.

Displaying record number 53002

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp120
Epitope	`RGPGRAFVTI`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	humanized mouse(H-2D^d)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	epitope processing, vaccine-induced immune responses, immunodominance, immunotherapy

Vaccine Details

Vaccine type	DNA, polyepitope
Vaccine strain	B clade MN
Vaccine component	gp120, Protease, RT
Adjuvant	Incomplete Freund's Adjuvant (IFA)

Notes

Immunization of HLA-A*0201-transgenic mice with synthetic genes encoding clusters of human A*0201 CTL epitopes located at the sites of drug resistance mutations, induced RT-specific cellular responses indicating the immunogenicity of these constructs. This vaccine strategy may be a first step towards a therapeutic vaccine against drug-resistant strains. This epitope was included as a mouse marker for a CD8+ T-cell response.

References

Isaguliants2004 Maria G. Isaguliants, Bartek Zuber, Andreas Boberg, Dan Sjöstrand, Sergey V. Belikov, Erik Rollman, Anne Kjerrström Zuber, Vladimir O. Rechinsky, Ann-Sofie Rytting, Clas F. R. Källander, Jorma Hinkula, Sergey N. Kochetkov, Margaret Liu, and Britta Wahren. Reverse Transcriptase-Based DNA Vaccines against Drug-Resistant HIV-1 Tested in a Mouse Model. Vaccine, 22(13-14):1810-1819, 16 Apr 2004. PubMed ID: 15068865. Show all entries for this paper.

Displaying record number 53147

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	R10I
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	vaccine
Experimental methods	Chromium-release assay, Cytokine production
Keywords	epitope processing, vaccine-induced immune responses, immunodominance

Vaccine Details

Vaccine type	DNA, virus-like particle (VLP), polyepitope
Vaccine component	Gag, p24 Gag, Env V3

Notes

A codon optimized gag DNA vaccine was compared to a myristylation defective gag and p24 alone, both of which lack signals for secretion from transfected cells. Gag-derived immunogens that were secreted as VLPs and those that remained intracellular (p24) each produced strong CTL responses, and neither the size of antigen nor cellular trafficking and localization significantly influenced the strength of humoral and cellular immune activation. The formation and release of VLPs was not essential for eliciting strong CTL. BALB/c mice were given the DNA vaccine by i.m. administration of plasmid DNA for the prime and boost.
Linking the region encoding the V3 immunodominant epitope to the gag gene did not diminish the response to the Gag p24 epitope A9I, but did enable a response to the V3 epitope.
Minigenes were made incorporating just 1 epitope, minitopes, carrying 1 of 3 murine class I epitopes linked to the Ad2-E3 protein-derived signal peptide to allow access of the epitope to the ER. Weak induction of cellular immune responses was observed, in contrast to the complex polyprotein.

References

Wild2004 Jens Wild, Alexandra Bojak, Ludwig Deml, and Ralf Wagner. Influence of Polypeptide Size and Intracellular Sorting on the Induction of Epitope-Specific CTL Responses by DNA Vaccines in a Mouse Model. Vaccine, 22(13-14):1732-1743, 15 Apr 2004. PubMed ID: 15068857. Show all entries for this paper.

Displaying record number 53427

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	Env(318-327)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	R10I
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	vaccine
Patient MHC/HLA	H-2D
Experimental methods	Intracellular cytokine staining
Keywords	vaccine antigen design

Vaccine Details

Vaccine type	vaccinia
Vaccine strain	B clade IIIB
Vaccine component	gp160

Notes

The endogenous processing of the HIV-1 envelope glycoprotein generates several different natural peptidic species presented by the H-2D molecule in infected cells, the 9-, 10-, and 11-mer peptides, GPGRAFVTI, RGPGRAFVTI, and QRGPGRAFVTI. CTL with the same antigenicity could recognize all three forms. The complexity of the binding peptides suggests naturally processed proteins could provide more variety as antigens, stimualting more robust and diverse CTL responses.

References

Samino2004 Yolanda Samino, Daniel López, Sara Guil, Patricia de León, and Margarita Del Val. An Endogenous HIV Envelope-Derived Peptide without the Terminal NH3+ Group Anchor Is Physiologically Presented by Major Histocompatibility Complex Class I Molecules. J. Biol. Chem., 279(2):1151-1160, 9 Jan 2004. PubMed ID: 14583622. Show all entries for this paper.

Displaying record number 53428

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	p18( IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	vaccine
Patient MHC/HLA	H-2D
Experimental methods	CD4 T-cell Elispot - IFNγ, CD8 T-cell Elispot - IFNγ, Chromium-release assay, Cytokine production, Proliferation
Keywords	vaccine-induced immune responses, memory cells, characterizing CD8+ T cells

Vaccine Details

Vaccine type	DNA with CMV promotor
Vaccine strain	B clade IIIB
Vaccine component	gp120
Adjuvant	IL-12

Notes

Delivery of plasmid IL-12 on day 10 after immunization of mice with an HIV-1 gp120 DNA vaccine resulted in expansion of gp120-specific CD8+ T-cells but had no effect on antigen-specific CD4+ T-cells and antibody responses. gp120-specific CD8+ T-cells were shown to primarly be effector memory and not central memory T-cells and did not expand following gp120 boost immunization.

References

Seaman2004 Michael S. Seaman, Fred W. Peyerl, Shawn S. Jackson, Michelle A. Lifton, Darci A. Gorgone, Jörn E. Schmitz, and Norman L. Letvin. Subsets of Memory Cytotoxic T Lymphocytes Elicited by Vaccination Influence the Efficiency of Secondary Expansion In Vivo. J. Virol., 78(1):206-15, Jan 2004. PubMed ID: 14671102. Show all entries for this paper.

Displaying record number 54603

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp120
Epitope	`RGPGRAFVTI`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	macaque, mouse(H-2D^d)
Immunogen	vaccine
Experimental methods	CD4 T-cell Elispot - IFNγ, Chromium-release assay, Other, Proliferation, Tetramer binding
Keywords	adjuvant comparison, vaccine antigen design, SIV

Vaccine Details

Vaccine type	DNA
Vaccine strain	B clade IIIB, SIV
Vaccine component	gp120

Notes

HIV-epitope, RGPGRAFVTI, was fused to a Heptatis B core antigen (HBcAg) gene in order to improve immunogenicity of an epitope-based vaccine in mice. A vaccine containing hybrid HBcAg-epitope linked to an HIV-specific T helper epitope induced significantly higher responses than a hybrid HBcAG-epitope vaccine which perfomed better than epitope alone. The authors suggest that HBcAg could be a better carrier of foreign epitopes than even Hepatitis B surface antigen (HBsAg) - (previously studied).
This work also deals with a multi-epitope SIV-based vaccine in non-human primates.

References

Fuller2007 Deborah Heydenburg Fuller, Tim Shipley, Todd M. Allen, James T. Fuller, Mary S. Wu, Helen Horton, Nancy Wilson, Georg Widera, and David I. Watkins. Immunogenicity of Hybrid DNA Vaccines Expressing Hepatitis B Core Particles Carrying Human AND Simian Immunodeficiency Virus Epitopes in Mice and Rhesus Macaques. Virology, 364(2):245-255, 1 Aug 2007. PubMed ID: 17428516. Show all entries for this paper.

Displaying record number 54791

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	Env (gp160)(318-327 HIV-1 IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	P18-I10
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	peptide-HLA interaction
Experimental methods	Chromium-release assay, Other
Keywords	binding affinity, structure

Notes

To study the critical amino acids of both TCR and MHC that interact with peptide P18-I10 of HIV-1 IIIB, the authors used a series of mutant substituted peptides. Peptides substituted with Ala at various positions showed that positions 322R, 324F and 327I were essential for binding to H2-D^d. Residue 325V was critical for interacting with TCR. By employing D-amino acid derived peptides as mutants in order to avoid charge, size and molecular weight differences, they also show that 325V is necessary for CTL-induced cytotoxic activity. Using two distinct CTL clones and molecular modeling they determined that TCR sequences of CDR1 and not CDR3 critically interact with 325V.
This 10-residue minimally active peptide lies within the immunodominant epitope, RIQRGPGRAFVTIGK, that belongs to gp160, the hypervariable region of Env. Substituted peptides used in this study were RGPGRAFiTI, RGPGRAFlTI, RGPGRAFaTI, RGPGRAFyTI, RGPGRAFfTI, RGPGRAFhTI, RGPGRAFtTI, RGPGRAFsTI, RGPGRAFeTI,RGPGRAFkTI, RGPGRAFrTI and RGPGRAFpTI. In addition, D-amino acid variants of the residues in parentheses were used - (r)GPGRAFVTI, RG(p)GRAFVTI, RGPG(r)AFVTI, RGPGR(a)FVTI, RGPGRA(f)VTI, RGPGRAF(v)TI, RGPGRAFV(t)I, RGPGRAFVT(i), RGPGRAF(i)TI, RGPGRAF(l)TI, RGPGRAF(a)TI, RGPGRAF(y)TI, RGPGRAF(f)TI, RGPGRAF(h)TI and RGPGRAF(t)TI.

References

Nakagawa2007 Yohko Nakagawa, Hiroto Kikuchi, and Hidemi Takahashi. Molecular Analysis of TCR and Peptide/MHC Interaction Using P18-I10-Derived Peptides with a Single D-Amino Acid Substitution. Biophys. J., 92(7):2570-2582, 1 Apr 2007. PubMed ID: 17208967. Show all entries for this paper.

Displaying record number 55322

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp120
Epitope	`RGPGRAFVTI`	Epitope Alignment
		Show epitope variants
Epitope Name	H
Subtype	A
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Intracellular cytokine staining, Other
Keywords	subtype comparisons, vaccine-induced immune responses, variant cross-reactivity, antagonism

Vaccine Details

Vaccine type	DNA with CMV promotor, modified vaccinia Ankara (MVA), DNA prime with modified vaccinia Ankara (MVA) boost, other
Vaccine strain	A clade, B clade, C clade Du422, other
Vaccine component	Gag, Nef, RT

Notes

Cross-clade vaccine recognition was studied using either single-, multi or several anatomically separated single-clade vaccines. Limited cross-clade response was seen with single-clade administrations. Multi-clade vaccines gave immune interference (antagonism and original antigenic sin), reducing CTL response. Simultaneously administered but anatomically separated vaccines from clades A, B, C decreased antagonism and increased immune responses.
No cross-reactivity was seen with epitope variants (iGPGqAFyat, fGPGqAFyTn, iGPGRAFyTt, iGPGqtFyat, iGlGqAlyTt, lGPGqAFyat, iGPGRAFyat, iGPGqvFyrt, mGPGRvFyTt) after immunization with Clade A containing index Epitope H, RGPGRAFVTI.

References

Larke2007 Natasha Larke, Eung-Jun Im, Ralf Wagner, Carolyn Williamson, Anna-Lise Williamson, Andrew J. McMichael, and Tomáš Hanke. Combined Single-Clade Candidate HIV-1 Vaccines Induce T Cell Responses Limited by Multiple Forms of In Vivo Immune Interference. Eur. J. Immunol., 37(2):566-577, Feb 2007. PubMed ID: 17230443. Show all entries for this paper.

Displaying record number 58166

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	( IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	I10
Subtype	B
Species (MHC/HLA)	human, mouse(H-2D^d)
Immunogen	HIV-1 infection, vaccine
Country	Argentina
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	subtype comparisons, vaccine antigen design

Vaccine Details

Vaccine type	DNA, vaccinia
Vaccine strain	B clade IIIB, CRF12 ARMA159
Vaccine component	gp160

Notes

Responses to subtype B and BF peptides were tested in mice immunized with either EnvB or EnvBF, and also among HIV-positive Argentinian patients infected with either subtype. Most responses were subtype-specific, thus highlighting the need for subtype diversity in vaccine design.
Responses were examined to peptides representing the C1, C2, and V3 regions of Env. B-infected patients had greater responses to all subtype B peptides, while BF-infected patients had greater responses to all BF peptides.
Human patients infected with subtype B virus had high magnitude responses to V3 loop peptide RGPGRAFVTI, while BF-infected patients had no response.

References

Monaco2011 Daniela C. Mónaco, Ana M. Rodríguez, María F. Pascutti, Mauricio Carobene, Juliana Falivene, Alejandro Gómez, Cynthia Maeto, Gabriela Turk, José L. Nájera, Mariano Esteban, and M. Magdalena Gherardi. T-Cell Immune Responses against Env from CRF12\_BF and Subtype B HIV-1 Show High Clade-Specificity that Can Be Overridden by Multiclade Immunizations. PLoS One, 6(2):e17185, 2011. PubMed ID: 21364754. Show all entries for this paper.

Displaying record number 58371

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	H
Subtype	A
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Cytotoxicity assay, Flow cytometric T-cell cytokine assay
Keywords	mother-to-infant transmission, immunodominance, vaccine antigen design

Vaccine Details

Vaccine type	Bacillus BCG prime with vaccinia Ankara (MVA) boost
Vaccine strain	A clade, multiple epitope immunogen
Vaccine component	p17 Gag, p24 Gag, Other

Notes

The HIVA polyprotein contains p24, p17, and a polyepitope string of conserved epitopes that were selected to have particularly good cross-reactive potential for the A-clade epidemic in Kenya [Hanke et al., Nat. Med., 6:951-955 (2000)]. A vaccine was constructed to include both HIVA and tuberculosis antigen 85A.
Robust responses were observed to immunodominant epitope H after mouse vaccination with either HIVA or the HIVA-85A fusion.

References

Hopkins2011 Richard Hopkins, Anne Bridgeman, Joan Joseph, Sarah C Gilbert, Helen McShane, and Tomáš Hanke. Dual Neonate Vaccine Platform against HIV-1 and M. tuberculosis. PLoS One, 6(5):e20067, 2011. PubMed ID: 21603645. Show all entries for this paper.

Displaying record number 58372

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	H, P18-I10
Subtype	A
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	vaccine
Experimental methods	Cytotoxicity assay, Intracellular cytokine staining
Keywords	mother-to-infant transmission, immunodominance, vaccine antigen design

Vaccine Details

Vaccine type	Bacillus BCG prime with vaccinia Ankara (MVA) boost
Vaccine strain	A clade, multiple epitope immunogen
Vaccine component	p17 Gag, p24 Gag, Other

Notes

The HIVA polyprotein contains p24, p17, and a polyepitope string of conserved epitopes that were selected to have particularly good cross-reactive potential for the A-clade epidemic in Kenya [Hanke et al., Nat. Med., 6:951-955 (2000)]. A candidate vaccine was constructed with Mycobacterium bovis bacillus Calmette-Guerin (BCG) as the vector.
Mouse response to immunodominant epitope H increased with increasing dose of vaccine and constituted up to 0.2% of all CD8+ splenocytes.

References

Im2007 Eung-Jun Im, Narcis Saubi, Goretti Virgili, Clare Sander, Denise Teoh, Jose M. Gatell, Helen McShane, Joan Joseph, and Tomáš Hanke. Vaccine Platform for Prevention of Tuberculosis and Mother-to-Child Transmission of Human Immunodeficiency Virus Type 1 through Breastfeeding. J. Virol., 81(17):9408-9418, Sep 2007. PubMed ID: 17596303. Show all entries for this paper.

Displaying record number 59282

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	epitope H
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Flow cytometric T-cell cytokine assay, Intracellular cytokine staining
Keywords	vaccine-induced immune responses

Vaccine Details

Vaccine type	modified vaccinia Ankara (MVA), adenovirus
Vaccine component	p17 Gag, p24 Gag

Notes

Mice were vaccinated with a construct consisting of the HIVconsv polyepitope plus the H epitope (RGPGRAFVTI), with the same construct given both as an adenovirus immunization and an MVA boost. Eight peptides elicited responses, 5 of which contained known epitopes. The remaining 3 peptides are considered to contain novel epitopes.
Epitope H (RGPGRAFVTI) was included in the vaccine construct and elicited a strong response in vaccinated mice.

References

Ondondo2014 Beatrice Ondondo, Sultan Abdul-Jawad, Anne Bridgeman, and Tomáš Hanke. Characterization of T-Cell Responses to Conserved Regions of the HIV-1 Proteome in BALB/c Mice. Clin. Vaccine Immunol., 21(11):1565-1572, Nov 2014. PubMed ID: 25230940. Show all entries for this paper.

Displaying record number 59453

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	Env
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	Peptide H
Subtype	C
Species (MHC/HLA)	mouse(H-2D^d)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Cytokine production
Keywords	vaccine-induced immune responses, vaccine antigen design

Notes

A recombinant auxotroph for pantothenate expressing Gag or RT, M.bovis rBCGΔCD, induced HIV-C RT-specific and truncated-Env-specific CTL response when used to immunize mice. Immune boost was provided by rMVA which expressed a polyprotein of Gag, RT, Tat, Nef and truncated Env. Higher numbers of total CTL and those specific to subdominant Gag and RT epitopes were detected, as well as higher frequencies of response to subdominant epitopes.
Env Peptide H, RGPGRAFVTI, was the dominant CTL epitope used to test for immune response. Immune responses to HIV-1 Gag, RT and Env can be achieved when a mixture of the rBCGΔpanCD vaccines is used.

References

Chapman2013 Rosamund Chapman, Helen Stutz, William Jacobs, Jr., Enid Shephard, and Anna-Lise Williamson. Priming with Recombinant Auxotrophic BCG Expressing HIV-1 Gag, RT and Gp120 and Boosting with Recombinant MVA Induces a Robust T Cell Response in Mice. PLoS One, 8(8):e71601, 20 Aug 2013. PubMed ID: 23977084. Show all entries for this paper.

Displaying record number 57935

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	H
Subtype	A
Species (MHC/HLA)	mouse(H-2D^d, H-2L^d)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Cytotoxicity assay, HLA binding, Intracellular cytokine staining
Keywords	immunodominance, vaccine antigen design, optimal epitope

Vaccine Details

Vaccine type	DNA, modified vaccinia Ankara (MVA)
Vaccine strain	A clade, multiple epitope immunogen
Vaccine component	p17 Gag, p24 Gag, Other

Notes

Using a candidate vaccine immunogen (HIVA), immunodominant epitopes were sequentially removed to test whether subdominant responses could be protective. Subdominant epitopes induced robust responses and became immunodominant in the absence of higher-ranked epitopes. Thus vaccines focused on less-variable regions with subdominant epitopes could be effective.
When this immunodominant epitope H (RGPGRAFVTI) was deleted, subdominant epitope P (IFQSSMTKI) became immunodominant.

References

Im2011 Eung-Jun Im, Jessie P. Hong, Yaowaluck Roshorm, Anne Bridgeman, Sven Létourneau, Peter Liljeström, Mary Jane Potash, David J. Volsky, Andrew J. McMichael, and Tomáš Hanke. Protective Efficacy of Serially Up-Ranked Subdominant CD8+ T Cell Epitopes against Virus Challenges. PLoS Pathog., 7(5):e1002041, May 2011. PubMed ID: 21625575. Show all entries for this paper.

Displaying record number 56265

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location
Epitope	`RGPGRAFVTI`	Epitope Alignment
Subtype	C
Species (MHC/HLA)	mouse(H-2K^d)
Immunogen	vaccine
Country	South Africa
Experimental methods	CD4 T-cell Elispot - IFNγ, CD8 T-cell Elispot - IFNγ, Flow cytometric T-cell cytokine assay
Keywords	vaccine-induced immune responses, Th1

Vaccine Details

Vaccine type	DNA, DNA prime with modified vaccinia Ankara (MVA) boost
Vaccine strain	C clade Du422, C clade Du151
Vaccine component	Gag, gp160 deletions, Nef, RT, Tat

Notes

A DNA (SAAVI DNA-C) and MVA (SAAVI MVA-C) vaccines vaccines were tested in BALB/c mice. Combining the vaccines in a DNA prime and MVA boost regimen increased the cumulative peptide response compared to the DNA vaccine alone 10-fold.
Th1 cytokine IFN-γ and TNF-α levels from HIV-specific CD8 and CD4 T cells increased 20- and 8- fold respectively, with a SAAVI MVA-C boost.
Effector and effector memory RT- and Env-epsific memory CD8 T cell subsets were boosted after MVA immunizations.
CD8 epitope RGPGRAFVTI was used for detection of IFN-γ-secreting cells.

References

Shephard2008 Enid Shephard, Wendy A. Burgers, Joanne H. Van Harmelen, James E. Monroe, Trish Greenhalgh, Carolyn Williamson, and Anna-Lise Williamson. A Multigene HIV Type 1 Subtype C Modified Vaccinia Ankara (MVA) Vaccine Efficiently Boosts Immune Responses to a DNA Vaccine in Mice. AIDS Res. Hum. Retroviruses, 24(2):207-217, Feb 2008. PubMed ID: 18240963. Show all entries for this paper.

Displaying record number 755

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp160(318-327 IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	mouse(H-2L^d)
Immunogen	vaccine
Experimental methods
Keywords

Vaccine Details

Vaccine type	vaccinia
Vaccine strain	B clade IIIB
Vaccine component	Env, Nef

Notes

An HIV-1 Env vaccine was targeted for rapid cytoplasmic degradation.
The rapidly degraded form rapidly stimulated CTL to this peptide, faster than the normal vaccinia-env.
The rapidly degraded form also stimulated greater specific CTL lysis and higher CTLp frequencies than normal Env.
Similar results were obtained for a Nef protein designed for rapid degradation.

References

Tobery1997 T. W. Tobery and R. F. Siliciano. Targeting of HIV-1 Antigens for Rapid Intracellular Degradation Enhances Cytotoxic T Lymphocyte (CTL) Recognition and the Induction of De Novo CTL Responses In Vivo after Immunization. J. Exp. Med., 185:909-920, 1997. CD8+ cytotoxic T lymphocytes (CTLs) have the ability to recognize and eliminate virally infected cells before new virions are produced within that cell. Therefore, a rapid and vigorous CD8+ CTL response, induced by vaccination, can, in principle, prevent disseminated infection in vaccinated individuals who are exposed to the relevant virus. There has thus been interest in novel vaccine strategies that will enhance the induction of CD8+ CTLs. In this study, we have tested the hypothesis that targeting an antigen to undergo more efficient processing by the class I processing pathway will elicit a more vigorous CD8+ CTL response against that antigen. Targeting a type I transmembrane protein, the HIV-1 envelope (env) protein, for expression in the cytoplasm, rather than allowing its normal co-translational translocation into the endoplasmic reticulum, sensitized target cells expressing this mutant more rapidly for lysis by an env-specific CTL clone. Additionally, a greatly enhanced de novo env-specifc CTL response was induced in vivo after immunization of mice with recombinant vaccinia vectors expressing the cytoplasmic env mutant. Similarly, targeting a cytoplasmic protein, HIV-1 nef, to undergo rapid cytoplasmic degradation induced a greatly enhanced de novo nef-specific CD8+ CTL response in vivo after immunization of mice with either recombinant vaccinia vectors or DNA expression plasmids expressing the degradation targeted nef mutant. The targeting of viral antigens for rapid cytoplasmic degradation represents a novel and highly effective vaccine strategy for the induction of enhanced de novo CTL responses in vivo. PubMed ID: 9120397. Show all entries for this paper.

Displaying record number 749

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp160
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	mouse(H-2^d17)
Immunogen	vaccine
Experimental methods
Keywords

Vaccine Details

Vaccine type	vaccinia

Notes

MVA is an attenuated vaccinia that can not replicate in mammalian cells -- strings of CTL epitopes were delivered and expressed in a MVA DNA vector.
INFγ and CTL activity were induced after a single vaccination.
An MVA boost enhanced the response.

References

Hanke1998b T. Hanke, T. J. Blanchard, J. Schneider, G. S. Ogg, R. Tan, M. Becker, S. C. Gilbert, A. V. Hill, G. L. Smith, and A. McMichael. Immunogenicities of Intravenous and Intramuscular Administrations of Modified Vaccinia Virus Ankara-Based Multi-CTL Epitope Vaccine for Human Immunodeficiency Virus Type 1 in Mice. J. Gen. Virol., 79:83-90, 1998. PubMed ID: 9460927. Show all entries for this paper.

Displaying record number 748

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	Env(318-327)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	mouse(H-2^d)
Immunogen
Experimental methods
Keywords	epitope processing, immunodominance

Notes

A series of protease and proteasome inhibitors was used to identify elements of the processing pathway of this epitope, called p18, both from within Env and from within a chimeric hepatitis B protein which allows proper processing.
Lactacystin, a proteasome inhibitor, partially inhibits endogenous processing of p18 epitope suggesting both a proteasome pathway and an additional pathway can be used.
Both TAP dependent and TAP-independent pathways can be used.
1,10-phenanthrolin (metallopeptidases inhibitor) blocks epitope presentation demonstrating metalloproteinase processing in the Tap-dependent pathway.
The Tap-independent pathway does not involve processing by metalloproteinases.
This epitope is immunodominant in mice, and is presented by multiple human HLA alleles -- it has been suggested that the high processing efficiency of this epitope might result in poor presentation of co-expressed epitopes.

References

Lopez2000 D. Lopez, B. C. Gil-Torregrosa, C. Bergmann, and M. Del Val. Sequential Cleavage by Metallopeptidases and Proteasomes Is Involved in Processing HIV-1 ENV Epitope for Endogenous MHC Class I Antigen Presentation. J. Immunol., 164:5070-5077, 2000. PubMed ID: 10799863. Show all entries for this paper.

Displaying record number 52969

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp120 (V3)( IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	mouse(H-2^d)
Immunogen	vaccine
Experimental methods	Chromium-release assay, Intracellular cytokine staining
Keywords	genital and mucosal immunity, memory cells, vaccine antigen design

Vaccine Details

Vaccine type	influenza
Vaccine strain	B clade IIIB
Vaccine component	Env V3

Notes

BALB/c mice were transiently infected vaginally with a recombinant influenza virus expressing an HIV CTL V3 epitope. Infection was promoted by prior progesterone treatment. This vaccination induced long-term cellular T-cell responses in mice. Responses were induced at both local mucosal and systemic sites against both influenza and V3 epitopes. Intranasal vaccination also resulted in T-cell responses in distant mucosal tissues.

References

Garulli2004 Bruno Garulli, Yoshihiro Kawaoka, and Maria R. Castrucci. Mucosal and Systemic Immune Responses to a Human Immunodeficiency Virus Type 1 Epitope Induced upon Vaginal Infection with a Recombinant Influenza A Virus. J. Virol., 78(2):1020-1025, Jan 2004. PubMed ID: 14694134. Show all entries for this paper.

Displaying record number 747

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	Env
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	mouse(H-2^d)
Immunogen	vaccine
Experimental methods
Keywords

Vaccine Details

Vaccine type	vaccinia, Sindbis
Vaccine component	Env V3

Notes

HIV-1 epitope p18 was expressed in two different vaccine vectors and the CTL response was compared in BALB/c mice.
Class I tetramer staining showed that up to 13% of the CD8+ splenocytes were p18 specific in the acute response using vaccinia, only 4% using Sindbis.
vp18 had more gamma IFN secreting splenocytes and activated CD4+ and CD8+ T cells.
The overall decline in CD8+ T cells in the transition into memory was 2-3 fold for both vectors.
Sindbis virus recombinants induced protective memory cytotoxic T cells, although reduced quantitatively, without vaccinia associated inflammation and replication.

References

Villacres1999 M. C. Villacres and C. C. Bergmann. Enhanced Cytotoxic T Cell Activity in IL-4-Deficient Mice. J. Immunol., 162:2663-2670, 1999. PubMed ID: 10072509. Show all entries for this paper.

Displaying record number 746

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	Env
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	mouse(H-2^d)
Immunogen	vaccine
Experimental methods
Keywords	Th1

Vaccine Details

Vaccine type	DNA
Vaccine strain	B clade IIIB
Vaccine component	gp160, Rev
Adjuvant	IL-12, IL-15, IL-2

Notes

A study of the DNA vaccine pCMV160IIIB/REV with IL-15 and IL-2 or IL-12 expression plasmids.
Intranasal immunization of BALB/c mice with HIV DNA and IL-15 plasmid induced increased Th1 and CTL responses.
Co-administration of IL-15 with IL-12 or IL-2 plasmids did not alter the effect of IL-15.
Both the CTL (peptide pulsed targets) and DTH response (injection of peptide into footpad) to this peptide was monitored.
The Ab response to NNTRKSIRIQRGPGRAFVTIGKIGN was monitored, and IL-15 co-administration resulted in a decrease in the IgG1/IgG2a ratio.

References

Xin1999 K. Q. Xin, K. Hamajima, S. Sasaki, T. Tsuji, S. Watabe, E. Okada, and K. Okuda. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Vaccine, 17:858-66, 1999. PubMed ID: 10067692. Show all entries for this paper.

Displaying record number 757

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp160(318-327 IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	mouse(H-2^d)
Immunogen	vaccine
Experimental methods
Keywords

Vaccine Details

Vaccine type	peptide
Vaccine component	CD4BS, HPG30, Env V3
Adjuvant	IL-12

Notes

B cell epitope HGP-30 also serves as a CTL epitope.
Vaccine combined HGP-30, V3 loop peptide variants, and CD4 binding site peptide.
IL-12 expression plasmid included with the vaccination enhanced the CTL response.

References

Hamajima1997 K. Hamajima, J. Fukushima, H. Bukawa, T. Kaneko, T. Tsuji, Y. Asakura, S. Sasaki, K. Q. Xin, and K. Okuda. Strong Augment Effect of IL-12 Expression Plasmid on the Induction of HIV-Specific Cytotoxic T Lymphocyte Activity by a Peptide Vaccine Candidate. Clin. Immunol. Immunopathol., 83:179-184, 1997. We previously reported that repeated inoculation of VC1, a macromolecular multicomponent peptide vaccine emulsified with Freund's adjuvant (VC1-F), induced high cytotoxic T lymphocyte (CTL) levels and a substantial level of multivalent antibodies which neutralized various human immunodeficiency virus type 1 (HIV-1) isolates. In the present study, we report that inoculation of VC1-F plus interleukin (IL)-12 expression plasmid can induce a higher antigen-specific CTL response compared to that with VC1-F alone. VC1-F plus IL-12 expression plasmid or VC1-F alone were inoculated to BALB/c mice twice at interval of 2 weeks. Two weeks after the second inoculation, spleen effector cells from these mice were examined. Stronger CTL responses against target cells were observed from the inoculation of VC1-F plus IL-12 plasmid than from that with VC-1F alone, but there was no difference in antibody induction. The inoculation of VC1 plus IL-12 plasmid also produced higher CTL activity than the inoculation of VC1 alone. These augmented CTL activities were not observed using target cells pulsed with non-HIV-specific peptides and different class I haplotype cells. These data demonstrate that co-inoculation of cell-mediated immune potent antigen and IL-12 plasmids can enhance the antigen-specific CTL response. This may be a potential approach for the induction of cellular immunization against HIV-1 and other diseases. PubMed ID: 9143379. Show all entries for this paper.

Displaying record number 766

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp120(318-327 IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	mouse(H-2^d)
Immunogen	vaccine
Experimental methods
Keywords

Vaccine Details

Vaccine type	fusion protein with anthrax delivery domain
Vaccine component	gp120

Notes

Anthrax lethal toxin can deliver proteins to the cytosol of eukaryotic cells.
A fusion protein linking the delivery domain of the anthrax protein to gp120 achieved cellular uptake, and gp120 was processed allowing presentation of this V3 epitope to CTL in vitro.

References

Goletz1997 T. J. Goletz, K. R. Klimpel, N. Arora, S. H. Leppla, J. M. Keith, and J. A. Berzofsky. Targeting HIV Proteins to the Major Histocompatibility Complex Class I Processing Pathway with a Novel gp120-Anthrax Toxin Fusion Protein. Proc. Natl. Acad. Sci. U.S.A., 94:12059-12064, 1997. PubMed ID: 9342362. Show all entries for this paper.

Displaying record number 753

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp120
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	mouse(H-2^d)
Immunogen	vaccine
Experimental methods
Keywords

Vaccine Details

Vaccine type	vaccinia

Notes

This murine epitope was incorporated into a vaccine of CTL epitopes expressed together including 20 HIV epitopes recognized by humans from 12 HLA types, one murine HIV epitope and three macaque HIV epitopes, delivered in a vaccinia virus Ankara (VVA) construct.
The murine vaccination was more effective at generating CTL when given i.v. rather than i.m.

References

Hanke1998c T. Hanke, J. Schneider, S. G. Gilbert, A. V. S. Hill, and A. McMichael. DNA Multi-CTL Epitope Vaccines for HIV and Plasmodium falciparum: Immunogenicity in Mice. Vaccine, 16:426-435, 1998. PubMed ID: 9607066. Show all entries for this paper.

Displaying record number 745

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp160
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	mouse(H-2^d)
Immunogen	vaccine
Experimental methods
Keywords

Vaccine Details

Vaccine type	DNA, vaccinia
Vaccine component	Env
Adjuvant	IL-12

Notes

Induction of HIV-1 specific CD8 gamma IFN secreting cells was enhanced when IL-12 and Env were given together in a prime, followed by a VV expressing Env boost.
If IL-12 was also delivered as a boost from the viral vector, impairment of the IL-12 effects was noted, indicating that the vaccination schedule can be a critical parameter for success with DNA and vaccinia vectors used in combination with immunomodulators.
The negative effect observed when IL-12 was delivered with the boost involved nitric oxide.

References

Gherardi2000 M. M. Gherardi, J. C. Ramirez, and M. Esteban. Interleukin-12 (IL-12) Enhancement of the Cellular Immune Response against Human Immunodeficiency Virus Type 1 Env Antigen in a DNA Prime/Vaccinia Virus Boost Vaccine Regimen Is Time and Dose Dependent: Suppressive Effects of IL-12 Boost Are Mediated by Nitric Oxide. J. Virol., 74:6278-6286, 2000. PubMed ID: 10864637. Show all entries for this paper.

Displaying record number 1475

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp160(318-327 IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	I-10
Species (MHC/HLA)	mouse(H-2^d)
Immunogen	in vitro stimulation or selection
Experimental methods
Keywords

Notes

Pre-incubation of HIV-1 (IIIB) gp160 specific CTL with peptide without APCs reduced cytolytic activity 3.5 fold and induced peptide concentration dependent IL-2 unresponsiveness that might be due to IL-2Rbeta down regulation.
An enhanced cytolytic activity was observed by addition of anti-IFN-gamma, TNF-alpha or MIP-1beta to I-10 suppressed CTLs.

References

Takahashi2001 M. Takahashi, Y. Nakagawa, J. A. Berzofsky, and H. Takahashi. Counter-regulation of cytolytic activity and cytokine production in HIV-1-specific murine CD8+ cytotoxic T lymphocytes by free antigenic peptide. Int. Immunol., 13(1):43-51, Jan 2001. URL: http://intimm.oupjournals.org/cgi/content/full/13/1/43. PubMed ID: 11133833. Show all entries for this paper.

Displaying record number 763

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp160(318-327 IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	mouse(H-2^d)
Immunogen	vaccine
Experimental methods
Keywords	Th1, Th2

Vaccine Details

Vaccine type	DNA
Vaccine strain	B clade IIIB
Vaccine component	gp160

Notes

Low-dosage 8 Br-cAMP given in combination with a DNA vaccine to BALB/c mice increased IgG and sIgA levels, and enhanced Th1, Th2 and CTL activity -- the adjuvant activity may be mediated by activation of the CMV promotor in the DNA vaccine.

References

Arai2000 H. Arai, K. Q. Xin, K. Hamajima, Y. Lu, S. Watabe, T. Takahashi, S. Toda, K. Okuda, I. Kudoh, M. Suzuki, and K. Okuda. 8 Br-cAMP enhances both humoral and cell-mediated immune responses induced by an HIV-1 DNA vaccine. Gene Ther., 7(8):694-702, Apr 2000. PubMed ID: 10800093. Show all entries for this paper.

Displaying record number 1481

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp160( IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	mouse(H-2^d)
Immunogen	vaccine
Experimental methods
Keywords	Th1, Th2

Vaccine Details

Vaccine type	vaccinia
Vaccine strain	B clade IIIB
Vaccine component	gp160

Notes

Helicobacter pylori induces Th1 responses early, but predominantly Th2 responses later in infection (at 6 weeks) -- differentiation of HIV-1 gp160 CD4+ help and CD8+ CTL effector cells in response to HIV gp160-vaccinia vaccination is impaired in BALB/c mice infected with H. pylori.

References

Shirai2001 M. Shirai, R. Fujinaga, T. Masaki, and J. A. Berzofsky. Impaired development of HIV-1 gp160-specific CD8(+) cytotoxic T cells by a delayed switch from Th1 to Th2 cytokine phenotype in mice with Helicobacter pylori infection. Eur. J. Immunol., 31(2):516-26, Feb 2001. PubMed ID: 11180117. Show all entries for this paper.

Displaying record number 765

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp120(318-327 IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	mouse(H-2^d, H-2^p, H-2^u)
Immunogen	vaccine
Experimental methods
Keywords

Vaccine Details

Vaccine type	vaccinia
Vaccine strain	B clade IIIB
Vaccine component	gp160

Notes

Three class I MHC, {H-2}^d,p,u, that differ in sequence and serology, cross-present this peptide to T cells of each of the other haplotypes.
The amino acids R, F, and I are each critical for strong CTL activity with all three MHC molecules.

References

Shirai1997 M. Shirai, S. Kozlowski, D. H. Margulies, and J. A. Berzofsky. Degenerate MHC Restriction Reveals the Contribution of Class I MHC Molecules in Determining the Fine Specificity of CTL Recognition of an Immunodominant Determinant of HIV-1 gp160 V3 Loop. J. Immunol., 158:3181-3188, 1997. The novel allogeneic presentation of an immunodominant determinant within the HIV-1 gp160 V3 loop by three different class I MHC molecules to the same CD8+ CTL is used to study the influence of the MHC molecule on the fine specificity of CTL recognition. We previously reported that four distinct class I molecules of H-2d,u,p,q presented the V3 decapeptide P18-I10 (RGPGRAFVTI) to CTL. Surprisingly, we found that H- 2d,u,p cells mutually cross-present the P18-I10 peptide to allogeneic CTL clones of each of the other haplotypes, whereas none of these cross- presents to H-2q CTL, nor do H-2q targets present to CTL of the other haplotypes. Here, we explore the critical amino acid residues for the cross-presentation using 10 variant peptides with single amino acid substitutions. The fine specificity examined using these mutant peptides presented by the same MHC class I molecule showed striking similarity among the CTL of each haplotype, expressing either V beta 8.1 or V beta 14. In contrast, the fine specificity is different between the distinct MHC class I molecules even for the lysis by the same CTL, as shown by reciprocal effects of the same substitutions. Thus, peptide fine specificity of a single TCR is influenced by changes in the class I MHC molecules presenting the Ag. PubMed ID: 9120272. Show all entries for this paper.

Displaying record number 53046

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp160
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	P18-I10
Subtype	B
Species (MHC/HLA)	mouse
Immunogen	vaccine
Experimental methods	Chromium-release assay
Keywords	genital and mucosal immunity

Vaccine Details

Vaccine type	vaccinia with H1 influenza HA gene cassette
Vaccine strain	B clade IIIB
Vaccine component	gp160

Notes

The intraepithelial compartment of the intestinal mucosa is shown to be a major site for preventing virus spread by thymus-derived CD8alphaß-positive Ag specific CTLs and CD8alpha,alpha+gamma,delta cells, which regulate virus spread in a P18-I10 vaccinia vector mouse infection model.

References

Kuribayashi2004 Hideki Kuribayashi, Ayako Wakabayashi, Masumi Shimizu, Hiroshi Kaneko, Yoshihiko Norose, Yohko Nakagawa, Jian Wang, Yoshihiro Kumagai, David H. Margulies, and Hidemi Takahashi. Resistance to Viral Infection by Intraepithelial Lymphocytes in HIV-1 P18-I10-Specific T-Cell Receptor Transgenic Mice. Biochem. Biophys. Res. Commun., 316(2):356-363, 2 Apr 2004. PubMed ID: 15020225. Show all entries for this paper.

Displaying record number 758

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp160(318-327 IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	R10I
Species (MHC/HLA)	mouse
Immunogen	vaccine
Experimental methods
Keywords	optimal epitope

Vaccine Details

Vaccine type	peptide
Vaccine strain	B clade IIIB
Vaccine component	Env V3

Notes

RGPGRAFVTI was defined as the optimal peptide for vaccination, out of RIQRGPGRAFVTIGK.
This peptide, in a carrier-free form in Freund's adjuvant, could stimulate Env specific CTL in BALB/c mice.

References

Nehete1995 P. N. Nehete, K. S. Casement, R. B. Arlinghus, and K. J. Sastry. Studies on In Vivo Induction of HIV-1 Envelope-Specific Cytotoxic T Lymphocytes by Synthetic Peptides from the V3 Loop Region of HIV-1 IIIB gp120. Cell. Immunol., 160:217-223, 1995. PubMed ID: 7720083. Show all entries for this paper.

Displaying record number 58848

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp160
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	P18-I10
Subtype	B
Species (MHC/HLA)	humanized mouse
Immunogen	in vitro stimulation or selection
Experimental methods	Chromium-release assay, Other
Keywords

Notes

Although TGF-β and IL-6 usually differentiate CTL into the non-cytotoxic state, in this study upon re-exposure to their specific antigen (RGPGRAFVTI, P18-I10) these treated CTLs were converted to the cytotoxic state. Splenocytes from a transgenic TCRαβ mouse expressing P18-I10-specific cells were, upon exposure to TGF-β and IL-6, found to be resistant to Fas-FasL apoptosis, insensitive to re-exposure to both TGF-β and IL-6 (in vitro) and capable of eliminating vaccinia virus expressing cells (by adoptive transfer in vivo)

References

Takaku2012 Shun Takaku, Yohko Nakagawa, Atsuko Owaki, Masumi Shimizu, Megumi Takahashi, and Hidemi Takahashi. Induction of Apoptosis-Resistant and TGF-beta-Insensitive Murine CD8+ Cytotoxic T Lymphocytes Specific for HIV-1 gp160. Cell. Immunol., 280(2):138-147, Dec 2012. PubMed ID: 23399840. Show all entries for this paper.

Displaying record number 767

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	Env( IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	mouse
Immunogen	vaccine
Experimental methods
Keywords

Vaccine Details

Vaccine type	DNA
Vaccine strain	B clade IIIB
Vaccine component	gp160, Rev
Adjuvant	MIP-1α

Notes

MIP-1alpha co-inoculation increased IgG1/IgG2a ratio T-helper type 1 response.
A MIP-1 alpha expression plasmid increased the CTL response to this DNA vaccine, as well as the T help response, presumably by the MIP-1 alpha interacting with T lymphocytes and macrophages.

References

Lu1999 Y. Lu, K. Q. Xin, K. Hamajima, T. Tsuji, I. Aoki, J. Yang, S. Sasaki, J. Fukushima, T. Yoshimura, S. Toda, E. Okada, and K. Okuda. Macrophage inflammatory protein-1alpha (MIP-1alpha) expression plasmid enhances DNA vaccine-induced immune response against HIV-1. Clin. Exp. Immunol., 115(2):335-41, Feb 1999. PubMed ID: 9933462. Show all entries for this paper.

Displaying record number 52016

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	P18
Subtype	B
Species (MHC/HLA)	mouse
Immunogen	vaccine
Experimental methods
Keywords

Vaccine Details

Vaccine type	DNA
Vaccine strain	B clade BH10
Vaccine component	gp120
Adjuvant	GM-CSF

Notes

gp120 encoding DNA co-injected with a plasmid carrying GMCSF gave meager CD4+ T-cell responses in BALB/c mice relative to the enhanced response to bicistronic gp120 and GMCSF cloned into the same vector and expressed from the same promoter.
Both mono and bicistronic DNA vaccines induced similar CTL responses directed against the H-2Dd restricted P18 peptide RGPGRAFTVTI in murine splenocytes despite the greatly enhanced proliferative responses.

References

Barouch2002 Dan H. Barouch, Sampa Santra, Klara Tenner-Racz, Paul Racz, Marcelo J. Kuroda, Joern E. Schmitz, Shawn S. Jackson, Michelle A. Lifton, Dan C. Freed, Helen C. Perry, Mary-Ellen Davies, John W. Shiver, and Norman L. Letvin. Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J. Immunol., 168(2):562-568, 15 Jan 2002. PubMed ID: 11777947. Show all entries for this paper.

Displaying record number 52188

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp120(313-322 BRU)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	Pep 09
Subtype	B, C
Species (MHC/HLA)	mouse
Immunogen	vaccine
Experimental methods
Keywords	subtype comparisons, Th1

Vaccine Details

Vaccine type	DNA
Vaccine strain	B clade BRU
Vaccine component	gp160, Rev, Tat

Notes

Plasmid DNA encoding gp160, tat, rev was given i.m. to immunize BALB/c mice.
Vaccine-induced CTL activity produced a low degree of cell lysis of V3-peptide pulsed target cells, using a B (RGPGRAFVTI) or C (RIGGPGQTFYATG) clade V3 peptides. Th1 proliferative T-cell responses were observed, and weak Ab responses.

References

Arora2001 A. Arora and P. Seth. Immunization with HIV-1 Subtype B gp160-DNA Induces Specific as Well as Cross Reactive Immune Responses in Mice. Indian J Med Res, 114:1-9, Jul 2001. PubMed ID: 11762199. Show all entries for this paper.

Displaying record number 744

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp160(318-327 IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	macaque
Immunogen	vaccine
Experimental methods
Keywords

Vaccine Details

Vaccine type	DNA prime with peptide boost
Vaccine strain	B clade IIIB
Vaccine component	CD4BS, gp160, HPG30, Env V3

Notes

Murine BALB/c (H-2^d) and macaque both showed highest level of CTL vaccine response when a DNA vaccine was boosted with a peptide including four peptide subtypes of the V3 region, HPG-30 and a fragment of the CD4 binding region.

References

Okuda1997 K. Okuda, K. O. Xin, T. Tsuji, H. Bukawa, S. Tanaka, W. C. Koff, K. Tani, K. Okuda, K. Honma, S. Kawamoto, K. Hamajima, and J. Fukushima. DNA vaccination followed by macromolecular multicomponent peptide vaccination against HIV-1 induces strong antigen-specific immunity. Vaccine, 15:1049-56, 1997. PubMed ID: 9269046. Show all entries for this paper.

Displaying record number 55283

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	Env
Epitope	`RGPGRAFVTI`	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human
Immunogen	vaccine
Country	United States
Experimental methods	Other, Tetramer binding
Keywords	memory cells

Vaccine Details

Vaccine type	vesicular stomatitis virus (VSV)
Vaccine strain	B clade
Vaccine component	Env

Notes

The requirement for CD4 T cell help in primary versus memory CTL responses was examined. Since a VSV vector encoding HIV Env was used as vaccine, responses specific to HIV-1 Env epitope RGPGRAFVTI as well as VSV epitope N were tested. Both primary and memory responses to the Env epitope did not require Th help. However, primary CTL responses to Env were 2-3 fold higher in the presence of CD4 T cells, while memory responses were tested until 3 months post-priming. Thus memory CTL maintenance dependency on CD4 T cell help is epitope-dependent.

References

Ramsburg2007 Elizabeth A. Ramsburg, Jean M. Publicover, Dagan Coppock, and John K. Rose. Requirement for CD4 T Cell Help in Maintenance of Memory CD8 T Cell Responses Is Epitope Dependent. J. Immunol., 178(10):6350-6358, 15 May 2007. PubMed ID: 17475864. Show all entries for this paper.

Displaying record number 55667

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp120
Epitope	`RGPGRAFVTI`	Epitope Alignment
Subtype	C
Species (MHC/HLA)	human, mouse
Immunogen	vaccine
Country	South Africa, United States
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	vaccine antigen design

Vaccine Details

Vaccine type	modified vaccinia Ankara (MVA)
Vaccine strain	C clade Du422
Vaccine component	Env, Gag, Nef, RT, Tat

Notes

5 genes from southern African HIV subtype C vaccine strains Du151 and Du422 were developed into a recombinant MVA polygene and were characterized in mice. A double recombinant, SAAVI MVA-C, was used to overcome genetic instability of env by inserting Grttn (gag, reverse transcriptase, tat and nef) and gp150 at 2 sites. Env infectivity as well as murine T-cell-immune response that was boosted by second inoculation were shown .
Peptides used to test for mouse CTL responses were H-2K(d)-restricted Gag AMQMLKDTI, H-2K(d)-restricted RT VYYDPSKDLIA and H-2D(d)-restricted Env RGPGRAFVTI.
Epitope RGPGRAFVTI from HIV gp120 was inserted at the 3'end of the gene to generate gp150CT in order to facilitate mouse anti-HIV immune assays.

References

Burgers2008 Wendy A. Burgers, Enid Shephard, James E. Monroe, Trish Greenhalgh, Anke Binder, Etienne Hurter, Joanne H. Van Harmelen, Carolyn Williamson, and Anna-Lise Williamson. Construction, Characterization, and Immunogenicity of a Multigene Modified Vaccinia Ankara (MVA) Vaccine Based on HIV Type 1 Subtype C. AIDS Res. Hum. Retroviruses, 24(2):195-206, Feb 2008. PubMed ID: 18240957. Show all entries for this paper.

Displaying record number 52715

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	Env( IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	10 Env
Subtype	B
Species (MHC/HLA)	mouse
Immunogen	vaccine
Patient MHC/HLA	H-2d
Experimental methods	CD8 T-cell Elispot - IFNγ, Cytokine production, Proliferation
Keywords	Th1, Th2, genital and mucosal immunity

Vaccine Details

Vaccine type	influenza prime with vaccinia boost
Vaccine strain	B clade IIIB
Vaccine component	gp160

Notes

Mice were intranasally primed with a recombinant influenza virus A vector that carries HIV-1 Env inserted into its hemagglutinin protein. Boosting was performed intranasally with either influenza-Env or intraperitoneally with two vaccinia virus recombinants expressing the Env protein, VVenv and MVAenv.
Peritoneal heterologous immunization with VVenv induced a 60-fold higher CD8+ IFN-gamma T cell responses than homologous influenza prime-boost. The intraperitoneal MVAenv boost response was greater than the VVenv boost in the spleen and genital lymph nodes, while the VVenv response gave the highest boost with the intranasal route.
Mice with increased CD8+-T-cell responses also had a higher Th1/Th2 ratio, indicated by the cytokine secretion profile and the IgG2a/IgG1 ratio.

References

Gherardi2003 M. Magdalena Gherardi, José Luis Nájera, Eva Pérez-Jiménez, Susana Guerra, Adolfo García-Sastre, and Mariano Esteban. Prime-Boost Immunization Schedules Based on Influenza Virus and Vaccinia Virus Vectors Potentiate Cellular Immune Responses against Human Immunodeficiency Virus Env Protein Systemically and in the Genitorectal Draining Lymph Nodes. J. Virol., 77(12):7048-7057, Jun 2003. PubMed ID: 12768024. Show all entries for this paper.

Displaying record number 57570

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	Env
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	H
Subtype	A
Species (MHC/HLA)	mouse
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords

Vaccine Details

Vaccine type	adenovirus
Vaccine strain	A clade
Vaccine component	Gag, Other

Notes

A novel ovine adenoviral vector (OAdV) was compared to human AdV5 vector for the delivery of HIV clade A vaccine in mice. The ovine vector primed T cells more efficiently, but was less persistent than AdV5.
Immunodominant epitope RGPGRAFVTI was used to assess the effectiveness of the vaccines.

References

Bridgeman2009 Anne Bridgeman, Yaowaluck Roshorm, Linda J. Lockett, Zheng-Zhou Xu, Richard Hopkins, Jan Shaw, Gerald W. Both, and Tomáš Hanke. Ovine Atadenovirus, a Novel and Highly Immunogenic Vector in Prime-Boost Studies of a Candidate HIV-1 Vaccine. Vaccine, 28(2):474-483, 11 Dec 2009. PubMed ID: 19853074. Show all entries for this paper.

Displaying record number 750

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp120(318-327)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Species (MHC/HLA)	human
Immunogen	HIV-1 infection
Experimental methods
Keywords

Notes

Increased CTL response to cells expressing a VV construct ΔV3 mutant compared with a full-length env gene product.
This epitope doesn't have A2 anchors, but has features that confer promiscuous A2 binding, which may relate to the inhibitory effect seen in this paper.

References

Kmieciak1998 D. Kmieciak, T. J. Wasik, H. Teppler, J. Pientka, S. H. Hsu, H. Takahashi, K. Okumura, Y. Kaneko, and D. Kozbor. The effect of deletion of the V3 loop of gp120 on cytotoxic T cell responses and HIV gp120-mediated pathogenesis. J. Immunol., 160:5676-83, 1998. PubMed ID: 9605175. Show all entries for this paper.

Displaying record number 58375

HXB2 Location	gp160(311-320) gp120(311-320) DNA(7155..7184)	gp160 Epitope Map
Author Location	gp120( IIIB)
Epitope	`RGPGRAFVTI`	Epitope Alignment
Epitope Name	L
Subtype	B
Species (MHC/HLA)	mouse
Immunogen	vaccine
Experimental methods	Cytokine production, Other
Keywords	vaccine antigen design

Vaccine Details

Vaccine type	DNA, bacteriophage coat protein
Vaccine strain	B clade IIIB
Vaccine component	gp120

Notes

Mice were immunized with variable epitope libraries (VELs) consisting of strain IIIB Env gp120 with many possible variants of CTL epitope L. Data from ELISA, dot blot, and biopanning indicated that both phage and DNA immunogens carrying a VEL (of L) induced antibodies capable of neutralizing HIV-1 Env in its native configuration including isolates highly resistant to neutralizing by potent mAbs.

References

Charles-Nino2011 Claudia Charles-Niño, Cesar Pedroza-Roldan, Monica Viveros, Goar Gevorkian, and Karen Manoutcharian. Variable Epitope Libraries: New Vaccine Immunogens Capable of Inducing Broad Human Immunodeficiency Virus Type 1-Neutralizing Antibody Response. Vaccine, 29(32):5313-5321, 18 Jul 2011. PubMed ID: 21600948. Show all entries for this paper.